Adherence of PARP inhibitor for frontline maintenance therapy in primary epithelial ovarian cancer: a cross-sectional survey.

Myong Cheol Lim Yumi Lee Da-Young Kim Sinae Kim Sang-Soo Seo Sokbom Kang Sang-Yoon Park Myong Cheol Lim

Published in: Journal of gynecologic oncology (2023)

Approximately one-fourth of patients with ovarian cancer are non-adherent to PARP inhibitors as maintenance treatment for newly diagnosed advanced ovarian cancer. The occupational status, type of PARP inhibitor, and QOC may affect adherence to PARP inhibitors.

Keyphrases

dna damage
dna repair
newly diagnosed
stem cells
adipose tissue
glycemic control
metabolic syndrome
bone marrow
combination therapy
smoking cessation